0000000000482399

AUTHOR

Minoli L

showing 2 related works from this author

First case in Italy of acquired resistance to oseltamivir in an immunocompromised patient with influenza A/H1N1v infection

2010

A pandemic influenza A/H1N1v strain with the neuraminidase H274Y mutation was detected in nasal secretions of a 2-year-old leukemic patient with influenza-like illness after 18 days of treatment with oseltamivir. At baseline, no drug-resistant virus was found, while 4 days after treatment initiation a mix- ture of wild-type and mutated virus was detected. After treatment interruption, the wild type influenza virus re-emerged and became prevalent in nasal secretions after a few days, suggesting the lower fitness of the mutated virus strain. The patient slowly improved concurrently with a decrease in virus load, which resulted negative 42 days after diagnosis. No other drug-resistant influenz…

Bodily SecretionsvirusesResistanceDrug ResistanceSettore MED/42 - Igiene Generale E Applicatamedicine.disease_causePandemic H1N1v Oseltamivir Resistancechemistry.chemical_compoundInfluenza A Virus H1N1 SubtypePandemicInfluenza A virusInfluenza A VirusViralChildViral LoadTreatment OutcomeInfectious DiseasesItalyChild PreschoolRNA ViralFemaleViral diseaseViral loadH1N1vSequence AnalysisH1N1v; Oseltamivir; Pandemic; Resistance; Amino Acid Substitution; Antiviral Agents; Bodily Secretions; Child Preschool; Female; Humans; Immunocompromised Host; Influenza A Virus H1N1 Subtype; Influenza Human; Italy; Molecular Sequence Data; Mutation Missense; Neuraminidase; Nose; Oseltamivir; RNA Viral; Sequence Analysis DNA; Treatment Outcome; Viral Load; Viral Proteins; Withholding Treatment; Drug Resistance Viral; Virology; Infectious DiseasesHumanOseltamivirMolecular Sequence DataMutation MissenseNeuraminidaseBiologyNoseAntiviral AgentsVirusresistanceImmunocompromised HostViral ProteinsOseltamivirVirologyDrug Resistance ViralInfluenza HumanmedicineHumansH1N1 SubtypePreschoolInfluenza-like illnessPandemicSequence Analysis DNADNAVirologyInfluenzaInfluenza; A/H1N1v; Oseltamivir; resistancechemistryAmino Acid SubstitutionWithholding TreatmentMutationbiology.proteinRNAA/H1N1vMissenseNeuraminidase
researchProduct

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are creat…

2009

Contains fulltext : 80963.pdf (Publisher’s version ) (Open Access) BACKGROUND: The extent to which mortality differs following individual acquired immunodeficiency syndrome (AIDS)-defining events (ADEs) has not been assessed among patients initiating combination antiretroviral therapy. METHODS: We analyzed data from 31,620 patients with no prior ADEs who started combination antiretroviral therapy. Cox proportional hazards models were used to estimate mortality hazard ratios for each ADE that occurred in >50 patients, after stratification by cohort and adjustment for sex, HIV transmission group, number of antiretroviral drugs initiated, regimen, age, date of starting combination antiretrovir…

MaleInfectious diseases and international health [NCEBP 13]Lymphoma030312 virologyEsophageal candidiasisCohort Studies0302 clinical medicineInterquartile range030212 general & internal medicineAIDS-RelatedLymphoma AIDS-Related0303 health sciencesMortality rateProgressive multifocal leukoencephalopathyHazard ratioPrognosis3. Good healthPathogenesis and modulation of inflammation [N4i 1]Infectious DiseasesCombinationDrug Therapy CombinationFemaleInfection and autoimmunity [NCMLS 1]HumanMicrobiology (medical)Adultmedicine.medical_specialtyPrognosiAnti-HIV Agentsantiretroviral therapyInfectious DiseaseArticleAIDS-Related Opportunistic Infection03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)Drug TherapyInternal medicinemedicineHumansAIDS-defining eventProportional Hazards ModelsAIDS-Related Opportunistic Infections/diagnosis/ mortality; Acquired Immunodeficiency Syndrome/complications/diagnosis/drug; therapy/ mortality; Adult; Anti-HIV Agents/ therapeutic use; Cohort Studies; Drug Therapy; Combination; Female; Humans; Lymphoma; AIDS-Related/diagnosis/mortality; Male; Prognosis; Proportional Hazards ModelsAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic Infectionsbusiness.industryProportional hazards modelPoverty-related infectious diseases [N4i 3]Anti-HIV Agentmedicine.diseasemortalityConfidence intervalImmunologyProportional Hazards ModelCohort Studiebusiness
researchProduct